PET scans for carcinoid tumours

Carcinoid tumours are generally discussed as well-differentiated neuroendocrine tumours. Many carry somatostatin receptors, so a receptor-targeted PET radiotracer may show disease sites and help guide treatment decisions. An FDG PET scan answers a different biological question and may be chosen when the tumour appears more aggressive.

PET detects signals from a small amount of radioactive tracer, while the CT component supplies detailed anatomy. When a somatostatin receptor tracer attaches to tumour receptors, areas of uptake can help identify the primary tumour, involved lymph nodes or disease elsewhere in the body. The scan may also show whether receptor-targeted treatment is a possible option.

FDG traces glucose use rather than somatostatin receptors. A clinician may request FDG PET when pathology, tumour behaviour or other imaging suggests faster-growing disease. Uptake is not interpreted alone: infection, inflammation and normal organs can also take up tracer, so the report is compared with CT or MRI, pathology and clinical findings.

Confirm the exact PET study on the appointment letter because preparation differs by radiotracer. Tell the imaging team about pregnancy, possible pregnancy, breastfeeding, diabetes, kidney problems, allergies, recent infection and all medicines. Mention long-acting or short-acting somatostatin medicines; the department will say whether their timing needs adjustment.

Follow the centre's instructions about food, fluids, exercise and medicine on the day. After tracer injection there is a quiet uptake period before imaging, and you will need to lie still on the scanner bed. The team can plan support if pain, anxiety or difficulty lying flat could interfere with the scan.

The PET appointment itself is not a reason to delay care for severe symptoms. Seek urgent assessment for marked breathing difficulty, fainting, new confusion, severe abdominal pain, persistent vomiting, or intense flushing with wheezing, dizziness or a racing heartbeat. These symptoms need clinical evaluation regardless of when imaging is booked.

A reaction to the radiotracer is uncommon, but tell staff immediately about swelling, hives, breathing trouble or sudden dizziness during the visit. After leaving, use emergency services for severe or rapidly worsening symptoms and tell them which tracer was administered if that information is available.

Ask which radiotracer is planned and why it suits the suspected tumour type. Useful follow-up questions include whether the scan is intended to find the original site, stage known disease, investigate a change, or assess receptor-targeted treatment.

When results are ready, ask which areas showed uptake, whether any finding could be inflammatory or otherwise non-cancerous, and whether another scan or biopsy is needed for clarification. Discuss how the findings change the treatment plan rather than focusing only on whether the report calls the scan positive or negative.